Celldex Therapeutics (NASDAQ:CLDX) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Friday.

Other equities analysts also recently issued reports about the stock. WBB Securities reaffirmed a “buy” rating and issued a $10.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, December 6th. HC Wainwright reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, November 7th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $9.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, September 26th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $7.05.

Shares of Celldex Therapeutics (NASDAQ:CLDX) traded down $0.02 during trading hours on Friday, reaching $3.05. 668,749 shares of the company’s stock traded hands, compared to its average volume of 1,086,486. Celldex Therapeutics has a 52 week low of $2.20 and a 52 week high of $4.02. The firm has a market cap of $417.48, a P/E ratio of -3.02 and a beta of 2.73.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.07. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. The business had revenue of $3.90 million for the quarter, compared to the consensus estimate of $1.30 million. During the same period in the prior year, the business posted ($0.29) earnings per share. Celldex Therapeutics’s revenue for the quarter was up 77.3% compared to the same quarter last year. equities analysts anticipate that Celldex Therapeutics will post -0.93 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Celldex Therapeutics by 7.8% during the second quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock worth $24,143,000 after buying an additional 708,095 shares during the last quarter. Meditor Group Ltd increased its position in Celldex Therapeutics by 8.8% during the third quarter. Meditor Group Ltd now owns 6,312,700 shares of the biopharmaceutical company’s stock worth $18,054,000 after buying an additional 512,700 shares during the last quarter. Northern Trust Corp increased its position in Celldex Therapeutics by 12.2% during the second quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock worth $4,992,000 after buying an additional 219,661 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Celldex Therapeutics by 3.6% during the third quarter. Dimensional Fund Advisors LP now owns 861,790 shares of the biopharmaceutical company’s stock worth $2,465,000 after buying an additional 29,604 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Celldex Therapeutics by 3.6% during the third quarter. Bank of New York Mellon Corp now owns 622,430 shares of the biopharmaceutical company’s stock worth $1,780,000 after buying an additional 21,905 shares during the last quarter. 52.46% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/06/celldex-therapeutics-cldx-raised-to-sell-at-bidaskclub.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.